درحال بارگذاري...
جستجو
| ایمیل دوست | |
| نام شما | |
| ایمیل شما | |
| کد مقابل را وارد نمایید | |
این صفحه برای دوست شما با موفقیت ارسال شد.
فهرست محتوای دیجیتالی
فهرست مطالب
فهرست نقدها
80 مرتبه مشاهده شده
Chronic kidney disease, dialysis, and transplantation : a companion to Brenner and Rector’s the Kidney
- ISBN: 9780323529785
- ISBN: 032352978X
- Call Number : WJ 378 C557 2019
- Title: Chronic kidney disease, dialysis, and transplantation : a companion to Brenner and Rector’s the Kidney / [edited by] Jonathan Himmelfarb, T. Alp Ikizler.
- Edition: Fourth edition.
- Publication, Distribution: Philadelphia : Elsevier, 2019.
- Physical Description:v, 779 p.: illustrations; 29 cm
- Notes: Complemented by Brenner and Rector’s the Kidney / [edited by] Karl Skorecki, Glenn M. Chertow, Philip A. Marsden, Maarten W. Taal, Alan S.L. Yu. Tenth edition. 2016
- Notes: Includes bibliographical references and index
- Subject: Renal Dialysis.
- Subject: Kidney Transplantation.
- Subject: Kidney Failure, Chronic -- therapy.
- Subject: Kidney Failure, Chronic -- complications.
- Added Entry: Himmelfarb, Jonathan editor.
- Added Entry: Ikizler, T. Alp editor.
- Added Entry: Brenner and Rector’s the Kidney Complemented by (expression) 10th edition
فهرست محتوای دیجیتالی
محتواي کتاب
فهرست مطالب
- Chronic Kidney Disease, Dialysis, and Transplantation: A Companion to Brenner and Rector’s The Kidney
- Copyright
- Section Editors
- List of Contributors
- Section I - Chronic Kidney Disease
- Chapter 1 - Chronic Kidney Disease: Definition, Epidemiology, Cost, and Outcomes
- Chapter 2 - Measurement and Estimation of Kidney Function
- Chapter 3 - Diabetic Kidney Disease
- Chapter 4 - Hypertensive Chronic Kidney Disease
- Introduction
- Potential Mechanisms of Renal Injury in Hypertension
- Diagnosis and Clinical Manifestations
- Therapeutics
- Therapeutic Agents
- Angiotensin Converting Enzime Inhibitors
- Angiotensin Receptor Blockers
- Combination Therapy ACEI and ARBs
- Direct Renin Inhibitors
- Aldosterone Antagonists
- Calcium Channel Blockers
- Adrenergic Blockers
- Conclusion
- Chapter 5 - Chronic Kidney Disease in the Elderly
- Introduction
- Kidney Structural and Physiologic Changes Associated With Aging
- Identification of CKD in Older Adults
- Characteristics of Older Adults With CKD
- Outcomes Associated With CKD in Older Adults
- Management of Specific Comorbidities and Characteristics in Older Adults With CKD
- Multimorbidity And Complexity In Older Adults With Chronic Kidney Disease
- Management Options in Advanced Renal Disease in Older Adults
- Chapter 6 - The Pediatric Patient With Chronic Kidney Disease
- Epidemiology of Pediatric CHRONIC KIDNEY DISEASE
- Defining Chronic Kidney Disease
- Natural History and Progression of Chronic Kidney Disease
- Prevention of Progression
- Growth Failure
- Nutritional Issues and Metabolic Concerns
- Neurocognitive Development and School Performance
- Anemia
- Mineral and Bone Disorders
- Cardiovascular Disease
- Quality of Life and Transitions to Adulthood
- Chapter 7 - Genetic Causes of Chronic Kidney Disease
- Section II - Complications and Management of Chronic Kidney Disease
- Chapter 8 - The Role of the Chronic Kidney Disease Clinic and Multidisciplinary Team Care
- Introduction
- Staging and Terminology for Chronic Kidney Disease and Effect on Need for Coordinated Care
- Overview of Chronic Kidney Disease Clinic
- Key Goals of Chronic Kidney Disease Care
- Preparation for Kidney Replacement Therapy
- Clinic Logistics
- Services
- Key Components of the Clinic
- Individual Roles
- Chronic Kidney Disease Clinic Role in Longitudinal Care: Different Stages of Chronic Kidney Disease
- Chronic Kidney Disease Clinic Role in Parallel Care: Integrating With Other Caregivers
- Other Benefits of the Chronic Kidney Disease Clinic and Organized Protocol-Based Care
- Recent and Future Studies
- Conclusion
- Chapter 9 - Anemia in Chronic Kidney Disease
- Chapter 10 - Mineral Bone Disorders in Chronic Kidney Disease
- Introduction
- Phosphorus
- Calcium
- Parathyroid Hormone
- Normal Physiology
- Abnormal Physiology in Chronic Kidney Disease
- Measurement of Parathyroid Hormone
- Management of Secondary Hyperparathyroidism
- Treatment of elevated parathyroid hormone in patients with chronic kidney disease stages 3 to 5, not on dialysis.In CKD stages 3...
- Treatment of elevated parathyroid hormone in chronic kidney disease stage 5D: Calcitriol and vitamin D analogs.The use of calcit...
- Treatment of elevated parathyroid hormone in chronic kidney disease stage 5D: Calcimimetics.Calcimimetics are a group of drugs t...
- Treatment of elevated parathyroid hormone: Parathyroidectomy.The need for parathyroidectomy to control secondary hyperparathyro...
- Fibroblast Growth Factor 23
- Normal Fibroblast Growth Factor 23 Physiology
- Conclusion
- Introduction
- Chapter 11 - Vitamin D Disorders in Chronic Kidney Disease
- Chapter 12 - Cardiovascular Disease in Chronic Kidney Disease
- Epidemiology
- Mechanisms of Cardiovascular Disease Risk in Chronic Kidney Disease
- Traditional Cardiovascular Disease Risk Factors
- Nontraditional Cardiovascular Disease Risk Factors
- Cardiovascular Disease Clinical Syndromes
- Structural Disease: Percardial and Valvular Conditions
- Arrhythmia and Sudden Cardiac Death
- Chapter 13 - Nutrient Metabolism and Protein-Energy Wasting in Chronic Kidney Disease
- The Role of the Kidney in Nutrient Homeostasis
- Rationale and Nutritional Requirements for Patients with Chronic Kidney Disease
- Protein-Energy Wasting in Chronic Kidney Disease
- Concept of Protein-Energy Wasting
- Causes of Protein-Energy Wasting in Chronic Kidney Disease
- Prevalence of Protein-Energy Wasting in Chronic Kidney Disease
- Consequences of Protein-Energy Wasting in Chronic Kidney Disease
- Nutrition Screening and Assessment
- Screening Tools
- Nutrition Assessment Tools
- Anthropometry and Body Composition
- Biochemistry
- Dietary Intake Assessment Methods
- Twenty-four-hour dietary recalls.The 24-hour diet recall method is a structural nutritional interview used to capture detailed i...
- Food diaries and records.Food diaries or records provide self-reported information of all food and drinks consumed by an individ...
- Food frequency questionnaires.FFQs are used to quantify usual nutrient intakes.120 The questionnaires consist of lists of foods ...
- Nutritional Assessment Scores
- Treatment of Protein-Energy Wasting in Chronic Kidney Disease
- Summary and Conclusions
- Chapter 14 - Inflammation in Chronic Kidney Disease
- Chronic Inflammation: A Maladaptive Response in a Particular Setting
- Chronic Persistent Inflammation in Chronic Kidney Disease
- Description of the Problem
- Etiology of Inflammation in Chronic Kidney Disease
- Immune Dysfunction Proper of Chronic Kidney Disease
- Oxidative Stress
- Fluid Overload and Sodium Expansion
- Metabolic Acidosis
- Comorbidities
- Bowel bacteria overgrowth and altered gut microbiota.The gut microbial community (microbiota) has an important role in the renal...
- Nutritional problems.Cachexia and obesity represent divergent manifestations of nutritional problems associated with CKD, and bo...
- Sleep apnea and hypoxia.The lung-kidney link has received very limited attention to date, although the mutual interrelations bet...
- Vitamin D deficiency.Intact kidney function plays a central role in vitamin D physiology, and low levels of 25-OHD and 1,25 dihy...
- Lifestyle Factors
- Genetic Predisposition
- Dialysis Technique
- Consequences of Inflammation in Chronic Kidney Disease
- Mortality
- Development and Progression of Chronic Kidney Disease
- Protein-Energy Wasting
- Vascular Calcification
- Anemia and Erythropoiesis-Stimulating Agent Resistance
- Depression and Cognitive Impairment
- Endocrine Disorders
- Thyroid hormones.Inadequate kidney function, in addition to other factors accompanying CKD such as inflammation, exerts an influ...
- Sex hormones.Testosterone deficiency or hypogonadism is a common finding in men with CKD. Although the high prevalence of hypogo...
- Hypothalamic–pituitary–adrenal.The HPA axis is a finely tuned neuroendocrine system that plays a main role in processes such as ...
- Other hormones.The inflammatory response inhibits the action of growth hormone (GH),181 as supported by forearm perfusion studie...
- Thyroid hormones.Inadequate kidney function, in addition to other factors accompanying CKD such as inflammation, exerts an influ...
- Insulin Resistance
- Premature Senescence
- Quality of Life
- Measuring Inflammation in Chronic Kidney Disease Patients
- C-Reactive Protein
- Interleukins
- IL-6.IL-6 (MW 22 to 27 kD) is produced by numerous types of immune cells, including monocytes, mesothelial cells, fibroblasts, a...
- IL-10.IL-10 (18 kD) is a product of immune-active cells, mainly monocytes and lymphocytes, and appears to have a critical role i...
- TNF-.TNF, a proinflammatory cytokine (17 kD) originally associated with killing of tumoral cells, has a pivotal role in regulati...
- Other cytokines.Other cytokines have also been found to be increased in patients with CKD. IL-12 and IL-18 are elevated during t...
- IL-6.IL-6 (MW 22 to 27 kD) is produced by numerous types of immune cells, including monocytes, mesothelial cells, fibroblasts, a...
- Other Biomarkers of Inflammation
- Managing the Inflamed Chronic Kidney Disease Patient
- Conclusions
- Acknowledgment
- Conflict of Interest
- Chapter 15 - Sleep Disorders in Chronic Kidney Disease
- Chapter 16 - Depression and Neurocognitive Function in Chronic Kidney Disease
- Epidemiology of Depression
- Differentiating Depression from Medical Illness
- Prevalence
- Sequelae of Depression
- Comorbidities of Depression
- Treatment of Depression
- Case Presentation
- Summary of Depression in Chronic Kidney Disease
- Prevalence of Neurocognitive Impairment
- Neurocognitive Functioning after Transplantation
- Sequelae of Neurocognitive Impairment
- Treatment of Neurocognitive Impairment
- Case Presentation (1)
- Summary of Neurocognitive Function in Chronic Kidney Disease
- Chapter 17 - Improving Drug Use and Dosing in Chronic Kidney Disease
- Assessment of Kidney Function for Drug Dosing, Including Special Populations
- General Pharmacokinetic and Pharmacodynamic Principles
- General Approach for Drug Regimen Design in Chronic Kidney Disease
- Dosing of Select Newer Agents in Chronic Kidney Disease
- Drug Dosing in Dialysis Patients
- Considerations For Drug Removal by Renal Replacement Therapies
- Case Example: Dosing Brivaracetam in Hemodialysis and Continuous Kidney Replacement Therapy
- Q1: Should Brivaracetam Dosing be Altered in This End-Stage Kidney Disease Patient
- Q2: Is Brivaracetam Dialyzable
- Q3: How Should Brivaracetam Dose be Altered in This Patient With Intermittent Hemodialysis
- Q4: What If This Patient had Acute Kidney Injury and was Receiving Continuous Venovenous Hemofiltration With the Following Conti...
- Case Example: Dosing Brivaracetam in Hemodialysis and Continuous Kidney Replacement Therapy
- Drug Interactions In Chronic Kidney Disease
- Importance Of Interdisciplinary Teams in Improving Chronic Kidney Disease Care
- Improving Chronic Kidney Disease Care During Transitions
- Informatics Approaches to Improve Chronic Kidney Disease Care
- Chapter 18 - The Pathophysiology of Uremia
- Uremia: The Clinical Syndrome
- Uremia and Solute Retention
- Solute Production
- Uremic Inflammation and Oxidative Stress
- Current Catalog of Uremic Solutes
- Treatment of Uremia
- Conclusions
- Chapter 19 - Timing, Initiation, and Modality Options for Renal Replacement Therapy
- Indications for Initiation of Dialysis in Chronic Kidney Disease
- Evolution of Clinical Practice Guidelines for Initiation of Dialysis
- Past Kidney Disease Outcomes Quality Initiative Recommendations for Timing of Initiation of Dialysis
- Initiation Dialysis Early and Late (IDEAL) Trial
- Current Kidney Disease Outcomes Quality Initiative Recommendations for Timing of Initiation of Dialysis
- Other Clinical Practice Guidelines for Timing of Initiation of Dialysis
- Trends in Timing of Initiation of Dialysis
- Preparation for Renal Replacement Therapy
- Dialysis Modality Selection
- In-Center Dialysis Modalities
- Frequent in-Center Hemodialysis
- Home Dialysis Modalities
- Transplantation
- Conclusions
- Chapter 20 - Ethical Challenges and the Role of Palliative Care in Kidney Disease
- Chapter 8 - The Role of the Chronic Kidney Disease Clinic and Multidisciplinary Team Care
- Section III - Dialysis
- Chapter 21 - Dialysis and End-Stage Kidney Disease: Epidemiology, Costs, and Outcomes
- Chapter 22 - Principles of Hemodialysis
- Chapter 23 - Vascular Access
- Chapter 24 - Hemodialysis Adequacy
- Chapter 25 - Hemodialysis-Associated Infections*
- Introduction
- Factors Contributing to Infections Among Hemodialysis Patients
- Microbial Contamination of Water
- Dialysis-Associated Pyrogenic Reactions
- Disinfection, Sterilization, and Environmental Cleaning in Dialysis Facilities
- Bloodstream Infections and Other Infections
- Hepatitis C Virus
- Hepatitis B Virus
- Hepatitis Delta Virus
- Human Immunodeficiency Virus Infection
- Other Emerging Infections
- Summary of Recommendations and Future Directions
- Chapter 26 - Acute Complications of Hemodialysis
- Chapter 27 - Frequent Hemodialysis: Physiological, Epidemiological, and Practical Aspects
- Definition of Terms
- History of Frequent Hemodialysis
- Physiological Rationale
- Benefits and Risks: Review of the Current Evidence
- Clinical Indications
- Prescriptions for Frequent Hemodialysis
- Implementing A Frequent Hemodialysis Program
- Economic Considerations
- Medication Dosing Considerations
- International Trends and Variation
- Overcoming Barriers in Uptake of Frequent Hemodialysis
- Frequent Hemodialysis in Children
- Future Directions
- Chapter 28 - Home Hemodialysis
- Chapter 29 - Peritoneal Physiology
- Peritoneal Anatomy
- Histology
- Peritoneal Blood Flow
- Peritoneal Lymphatics
- Peritoneal Local Reaction to Infection
- Peritoneal Transport Physiology
- Barriers to Transperitoneal Exchange
- Modeling of Peritoneal Transport
- Fluid Transport
- Solute Transport
- Diffusive Transport
- Convective Transport
- Tests to Assess Peritoneal Transport
- Effluent Soluble Markers of the Peritoneal Membrane
- Factors Affecting Peritoneal Transport
- Effect of Body Posture on Peritoneal Transport
- Effect of Dialysate Composition on Peritoneal Transport
- Effect of pH and Different Buffers on Peritoneal Transport
- Effect of Biocompatible Solutions on Peritoneal Transport
- Pharmacological Effects on Peritoneal Transport
- Changes in Peritoneal Transport During Peritonitis
- Changes in Water and Solute Transport With Time on Peritoneal Dialysis
- Changes in Peritoneal Transport With Long-Term Peritoneal Dialysis
- Relation Between Peritoneal Transport Characteristics and Clinical Outcome
- Changes in Peritoneal Morphology With Time on Peritoneal Dialysis
- Pathophysiological Considerations
- Chapter 30 - The Use and Outcomes of Peritoneal Dialysis
- Peritoneal Dialysis Use
- Framework for Understanding Peritoneal Dialysis Use
- Identification of Potential Peritoneal Dialysis Patients
- Assessment of Peritoneal Dialysis Eligibility
- Offer and Choice
- Insertion of the Peritoneal Dialysis Catheter
- Receipt of Peritoneal Dialysis
- Outcomes of Peritoneal Dialysis Therapy
- Attempts at Randomized Comparisons of Peritoneal Dialysis and Hemodialysis
- Data Validity
- Comparing the Outcomes of Patients Treated With Peritoneal Dialysis and Hemodialysis: Survival
- Comparing the Outcomes of Patients Treated With Peritoneal Dialysis and Hemodialysis: Hospitalization
- Comparing the Outcomes of Patients Treated With Peritoneal Dialysis and Hemodialysis: Cost
- Comparing the Outcomes of Patients Treated With Peritoneal Dialysis and Hemodialysis: Quality of Life
- Summary
- Peritoneal Dialysis Use
- Chapter 31 - Peritoneal Dialysis Solutions, Prescription and Adequacy
- Peritoneal Dialysis Solutions
- Constituents of Peritoneal Dialysis Solutions
- Dialysate Buffer
- Dialysate Calcium
- Glucose-Based Solutions
- Non–Glucose-Based Peritoneal Dialysis Solutions
- Glucose Polymer Solutions
- Effects on ultrafiltration, volume status, and technique survival.Over the years, considerable clinical data demonstrated the ef...
- Effects on metabolic profile.Use of icodextrin as the long-dwell solution also minimizes glucose exposure and incurs less metabo...
- Effects on residual kidney function.Although there were some earlier suggestions that increased ultrafiltration with icodextrin ...
- Potential adverse effects.Use of icodextrin may be associated with potential adverse events such as sterile peritonitis or skin ...
- Biocompatible Peritoneal Dialysis Solutions
- Effects on residual kidney function and urine volume.The Euro Balance Trial123 was the first RCT that examined the effects of ne...
- Effects on peritonitis risk.In the balANZ trial, the time to first peritonitis episode was longer and overall peritonitis rates ...
- Effects on peritoneal solute transport and ultrafiltration volume.The effects of biocompatible solutions on ultrafiltration volu...
- Other clinical outcomes.Earlier studies suggested a potential benefit in reducing inflow pain with more biocompatible PD solutio...
- Amino Acid Peritoneal Dialysis Solutions
- Low-Sodium Peritoneal Dialysis Solutions
- Glucose Polymer Solutions
- Future Development in Peritoneal Dialysis Solutions
- Conclusions
- Dialysis Adequacy and Prescription
- Defining Dialysis Adequacy
- Measuring Biochemical Indices of Dialysis Adequacy
- Normalization Factor for Urea and Creatinine Clearance
- Estimation of Residual Kidney Function
- Frequency of Monitoring of Biochemical Indices of Dialysis Adequacy
- Peritoneal Equilibration Test
- Importance of Dialysis Adequacy and Defining Numerical Targets for Biochemical Indices of Dialysis Adequacy
- Ultrafiltration and Volume Control as a Target for Dialysis Adequacy
- Nutrition Status as a Target for Dialysis Adequacy
- Initial Peritoneal Dialysis Prescription
- Clinical Evaluation of Patients With Low Delivered Urea Clearance
- Adjusting Peritoneal Dialysis Prescription
- High Transporters
- Factors Contributing to More Adverse Outcomes in High Transporters
- Acute Membrane Injury
- Ultrafiltration Failure
- Conclusions (1)
- Residual Kidney Function
- Importance of Residual Kidney Function in Peritoneal Dialysis
- Decline of Residual Kidney Function
- How Can We Better Preserve Residual Kidney Function in Peritoneal Dialysis Patients
- Biocompatible low-GDP solutions.The effects of biocompatible low-GDP solution on RKF have been examined in several RCTs (detaile...
- Renin-angiotensin system blockers.The efficacy of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in p...
- Ketoacid-supplemented low-protein diet.There is some preliminary suggestion that a ketoacid-supplemented low-protein diet may be...
- N-acetylcysteine.Two small single-arm pilot studies, one in PD and one in hemodialysis patients, suggested that oral N-acetylcys...
- Diuretics.The role of diuretics is mainly to increase urine volume and sodium excretion and minimize use of hypertonic PD glucos...
- Aminoglycosides.Given the nephrotoxicity of aminoglycosides, use of aminoglycosides should be cautioned in PD patients to minimi...
- Iodinated radiocontrast.Because iodinated radiocontrast agents can cause acute tubular necrosis and acute kidney injury, its use...
- PD modality.There has been some suggestion that APD might be associated with a more rapid decline in RKF than CAPD.276,277 Howev...
- Monitoring of RKF
- How Can We Better Preserve Residual Kidney Function in Peritoneal Dialysis Patients
- Conclusion
- Peritoneal Dialysis Solutions
- Chapter 32 - Peritoneal Dialysis-Related Infections
- Peritoneal Dialysis-Related Peritonitis
- Pathogenesis
- Host Defense Mechanisms of the Peritoneal Cavity
- Presentation
- Diagnosis
- Treatment of Peritonitis
- Mycobacterial Peritonitis
- Complications of Peritoneal Dialysis Peritonitis
- Catheter-Related Infections
- Prevention
- Peritoneal Dialysis-Related Peritonitis
- Chapter 33 - Noninfectious Complications of Peritoneal Dialysis
- Complications Related to Increased Intraabdominal Pressure
- Hernia Formation
- Dialysate Leaks
- Hydrothorax
- Pathogenesis
- Incidence and Risk Factors
- Clinical Presentation
- Diagnosis
- Management
- Temporary Interruption of Peritoneal Dialysis (Conservative Management).There is a clear consensus that interruption of PD shoul...
- Pleurodesis.Pleurodesis is another option for repairing the pleuroperitoneal communication leading to hydrothorax. This method i...
- Surgical Intervention.VATS has become the preferred modality to obliterate the diaphragmatic defect as the pleuroperitoneal comm...
- Malfunction of the Peritoneal Catheter
- Drain Pain
- Hemoperitoneum
- Chyloperitoneum
- Metabolic Complications
- Electrolyte Disorders
- Encapsulating Peritoneal Sclerosis
- Definition and Epidemiology
- Risk Factors
- Pathophysiology
- The “Two-hit” Hypothesis.The “two-hit” hypothesis is based on the principle that two events or insults are required for the deve...
- Clinical Presentation and Diagnosis.EPS is a slowly progressive disorder that may remain asymptomatic for a prolonged period of ...
- Biomarkers.A number of biomarkers have been studied in the PD effluent. It has been suggested that potential diagnostic markers ...
- Therapeutic Approaches in Encapsulating Peritoneal Sclerosis
- Conservative Measures.As previously mentioned, GI symptoms are pervasive in EPS. As a result, patients often decrease their oral...
- Corticosteroids.CCSs have become paramount in the treatment of EPS, with some studies documenting response rates as high as 100%...
- Tamoxifen.Tamoxifen is a selective estrogen receptor modulator with antifibrotic properties used in the treatment of various fib...
- Surgical Management.Despite the use of steroids and tamoxifen in the management of EPS, approximately 50% of patients do not res...
- Immunotherapy and Other Experimental Agents.There are reports in the literature of immunosuppressants being used to treat EPS.18...
- Prevention of Encapsulating Peritoneal Sclerosis
- Definition and Epidemiology
- Encapsulating Peritoneal Sclerosis and Renal Transplantation
- Complications Related to Increased Intraabdominal Pressure
- Section IV - Transplantation
- Chapter 34 - The Epidemiology, Outcomes, and Costs of Contemporary Kidney Transplantation
- Introduction
- Living Donor Transplantation
- Immunosuppression: Trends and Current Practice
- Posttransplant Outcomes
- Center Performance Grading
- Unmeasured and Novel Risk Factors
- Economics of Kidney Transplantation
- Economic Implications of Practice Innovation: ABO- and HLA-Incompatible Kidney Transplantation
- Conclusions
- Chapter 35 - Transplantation Immunobiology
- Chapter 36 - Evaluation of Donors and Recipients
- Evaluation of the Living Donor
- Clinical Assessment of the Living Donor
- Surgical Techniques and Risks
- Long-Term Risks to the Donor
- Conclusions
- Evaluation of the Recipient
- Clinical Assessment of the Recipient
- Selected Issues in the Recipient Evaluation
- Cardiovascular Disease
- Diabetes Mellitus
- Pulmonary Disease
- Cancer
- Obesity
- Infections
- Systemic Diseases
- Emerging Risk Factors That May Affect Kidney Transplant Candidacy
- History of a Failed Allograft
- High Sensitization to Human Leukocyte Antigens
- Psychosocial Issues
- Counseling and Education
- Management of the Waiting List
- Conclusions (1)
- Chapter 37 - Surgical Management of the Renal Transplant Recipient
- Chapter 38 - Immunosuppressive Therapy
- Chapter 39 - Diagnosis and Therapy of Graft Dysfunction
- Introduction
- Delayed Graft Function
- Other Causes of Graft Dysfunction During the First Week After Transplantation
- Acute Rejection
- Types of Acute Rejection
- Calcineurin Inhibitor-Mediated Nephrotoxicity
- Thrombotic Microangiopathy
- Infection
- Vascular Complications
- Late Graft Dysfunction
- Differential Diagnosis of Chronic Allograft Injury
- Antigen-Dependent Causes of Late Graft Loss
- Histocompatibility
- Prior Sensitization
- Alloantigen-Independent Factors
- Donor Age
- Chronic CNI Nephrotoxicity
- Histopathological Features of Chronic Graft Dysfunction
- Strategies to Prevent Late Graft Loss (Also See Chapter 44)
- BK Nephropathy
- Recurrent Diseases
- Nonadherence
- Acknowledgments
- Chapter 40 - Infection in Renal Transplant Recipients
- Introduction
- Pretransplant Recipient Evaluation
- Donor Evaluation
- Timeline of Infection
- Selected Infections of Importance
- Fungal Pathogens
- Bacterial Infections
- Prevention
- Chapter 41 - Noninfectious Complications After Kidney Transplantation
- Chapter 42 - Recurrent and De Novo Renal Diseases After Kidney Transplantation
- Chapter 43 - Pediatric Renal Transplantation
- Role of Transplantation
- Pretransplant Preparation
- The Transplantation Procedure
- Allograft Dysfunction
- Graft Survival
- Growth After Transplantation
- Complications of Pediatric Renal Transplantation
- Long-Term Outcomes of Pediatric Renal Transplantation
- Chapter 44 - Chronic Kidney Disease in the Kidney Transplant Recipient
- Chapter 34 - The Epidemiology, Outcomes, and Costs of Contemporary Kidney Transplantation
- Section V - Acute Kidney Injury
- Chapter 45 - The Epidemiology of Acute Kidney Injury
- Chapter 46 - Metabolic and Nutritional Complications of Acute Kidney Injury
- Chapter 47 - Acute Kidney Injury Diagnostics and Biomarkers
- Chapter 48 - Pharmacological Interventions in Acute Kidney Injury
- Barriers to Successful Clinical Trials in Acute Kidney Injury
- Pharmacological Interventions
- What Drugs Are on the Horizon
- Disclosures
- Chapter 49 - Renal Replacement Therapy for Acute Kidney Injury
- Index